miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells

Journal of Cellular and Molecular Medicine

Volumn 20, Issue 3, 2016, Pages 559-567

  Zeng, Li Ping ^a   Hu, Zheng Mao ^a   Li, Kai ^b   Xia, Kun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Clinical Laboratory of No 261 Hospital of the People's Liberation Army   (China)

Author keywords

Bladder cancer; Cisplatin; MicroRNA 222

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 222; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MICRORNA; MIRN222 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R2A PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGY; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER CELL CULTURE; CELL DEATH; CELL PROLIFERATION ASSAY; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; BINDING SITE; BLADDER TUMOR; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BINDING SITES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 84958629883     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12760     Document Type: Article

References (35)

1. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007; 282: 23716-24.
2. Mao KP, Zhang WN, Liang XM, et al. MicroRNA-222 expression and its prognostic potential in non-small cell lung cancer. ScientificWorldJournal. 2014; 2014: 908326.
3. Chen WX, Hu Q, Qiu MT, et al. miR-221/222: promising biomarkers for breast cancer. Tumour Biol. 2013; 34: 1361-70.
4. Wong QW, Ching AK, Chan AW, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res. 2010; 16: 867-75.
5. Zhang DQ, Zhou CK, Jiang XW, et al. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 2014; 12: 241.
6. Yang YF, Wang F, Xiao JJ, et al. MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med. 2014; 7: 893-902.
7. Gan R, Yang Y, Yang X, et al. Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. Cancer Gene Ther. 2014; 21: 290-6.
8. Garofalo M, Quintavalle C, Romano G, et al. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med. 2012; 12: 27-33.
9. Tatokoro M, Koga F, Yoshida S, et al. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells. Int J Cancer. 2012; 131: 987-96.
10. Huang PH, Wang D, Chuang HC, et al. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis. 2009; 30: 1125-31.
11. Switzer CH, Ridnour LA, Cheng RY, et al. Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. Oncogene. 2009; 28: 3837-46.
12. Kar S, Palit S, Ball WB, et al. Carnosic acid modulates Akt/IKK/NF-kappaB signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis. 2012; 17: 735-47.
13. Wang JY, Chang CC, Chiang CC, et al. Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem. 2012; 113: 1733-43.
14. Bos CL, Diks SH, Hardwick JC, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006; 27: 2371-82.
15. Zimmerman R, Peng DJ, Lanz H, et al. PP2A inactivation is a crucial step in triggering apoptin-induced tumor-selective cell killing. Cell Death Dis. 2012; 3: e291.
16. Shen M, Duan WM, Wu MY, et al. Participation of autophagy in the cytotoxicity against breast cancer cells by cisplatin. Oncol Rep. 2015; 34: 359-67.
17. Calderaro J, Rebouissou S, de Koning L, et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014; 134: 1776-84.
18. Veerla S, Lindgren D, Kvist A, et al. MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer. 2009; 124: 2236-42.
19. Puerta-Gil P, Garcia-Baquero R, Jia AY, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012; 180: 1808-15.
20. Chen W, Wang Z, Jiang C, et al. PP2A-mediated anticancer therapy. Gastroenterol Res Pract. 2013; 2013: 675429.
21. Schonthal AH. Role of serine/threonine protein phosphatase 2A in cancer. Cancer Lett. 2001; 170: 1-13.
22. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001; 353: 417-39.
23. Virshup DM. Protein phosphatase 2A: a panoply of enzymes. Curr Opin Cell Biol. 2000; 12: 180-5.
24. Dong R, Zheng Y, Chen G, et al. miR-222 overexpression may contribute to liver fibrosis in biliary atresia by targeting PPP2R2A. J Pediatr Gastroenterol Nutr. 2015; 60: 84-90.
25. Shen WJ, Dong R, Chen G, et al. microRNA-222 modulates liver fibrosis in a murine model of biliary atresia. Biochem Biophys Res Commun. 2014; 446: 155-9.
26. Zhang Y, Ma T, Yang S, et al. High-mobility group A1 proteins enhance the expression of the oncogenic miR-222 in lung cancer cells. Mol Cell Biochem. 2011; 357: 363-71.
27. Dong Y, Liang G, Yuan B, et al. MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway. Tumour Biol. 2015; 36: 1477-86.
28. Boscolo E, Coma S, Luks VL, et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis. 2015; 18: 151-62.
29. Singh AR, Joshi S, George E, et al. Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int. 2014; 14: 105.
30. Zhong C, Ding S, Xu Y, et al. MicroRNA-222 promotes human non-small cell lung cancer H460 growth by targeting p27. Int J Clin Exp Med. 2015; 8: 5534-40.
31. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Bio Chem. 2008; 283: 31079-86.
32. Garofalo M, Quintavalle C, Di Leva G, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008; 27: 3845-55.
33. du Moon G, Lee SE, Oh MM, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol. 2014; 45: 1027-35.
34. Garcia-Cano J, Ambroise G, Pascual-Serra R, et al. Exploiting the potential of autophagy in cisplatin therapy: a new strategy to overcome resistance. Oncotarget. 2015; 6: 15551-65.
35. Hu F, Wei F, Wang Y, et al. EGCG synergizes the therapeutic effect of cisplatin and oxaliplatin through autophagic pathway in human colorectal cancer cells. J Pharmacol Sci. 2015; 128: 27-34.